NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

MURA

Mural Oncology plc

Apr 21 • 10:35AM ET

2.71

Dollar change +0.01
Percentage change 0.37	%

Healthcare • Biotechnology • Ireland • NASD

Peers: MRNA BMY PFE GILD AMGN LLY JNJ AZN REGN BNTX

| Held by: VTI VXF IWC VHT MEDX BTEC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-7.58	Insider Own	10.97%	Shs Outstand	17.10M	Perf Week	163.11%
Market Cap	46.69M	Forward P/E	-	EPS next Y	-2.30	Insider Trans	-1.97%	Shs Float	15.34M	Perf Month	-29.97%
Income	-128.51M	PEG	-	EPS next Q	-2.04	Inst Own	52.69%	Short Float	3.88%	Perf Quarter	-32.25%
Sales	0.00M	P/S	-	EPS this Y	29.52%	Inst Trans	-19.99%	Short Ratio	0.13	Perf Half Y	-27.15%
Book/sh	8.22	P/B	0.33	EPS next Y	57.00%	ROA	-54.55%	Short Interest	0.59M	Perf Year	-27.93%
Cash/sh	8.38	P/C	0.32	EPS next 5Y	37.41%	ROE	-63.57%	52W Range	0.95 - 4.74	Perf YTD	-15.84%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-89.89%	52W High	-42.83%	Beta	0.62
Dividend TTM	-	Quick Ratio	5.83	Sales past 5Y	5.55%	Gross Margin	-	52W Low	185.26%	ATR (14)	0.35
Dividend Ex-Date	-	Current Ratio	5.83	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	60.16	Volatility	17.45% 14.61%
Employees	116	Debt/Eq	0.06	Sales Y/Y TTM	-	Profit Margin	-	Recom	2.25	Target Price	8.67
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	43.71%	Payout	-	Rel Volume	0.56	Prev Close	2.70
Sales Surprise	-	EPS Surprise	-1.11%	Sales Q/Q	-	Earnings	Mar 11 AMC	Avg Volume	4.67M	Price	2.71
SMA20	69.35%	SMA50	-9.46%	SMA200	-18.89%	Trades		Volume	544,666	Change	0.37%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-25-25	Downgrade	Raymond James	Strong Buy → Outperform	$18
Mar-25-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-28-24	Initiated	Rodman & Renshaw	Buy	$15
Apr-04-24	Initiated	Morgan Stanley	Overweight	$13

Apr-16-25 09:48AM	MURA Soars as it Explores Strategic Options Post Cancer Study Failures (Zacks)
Apr-15-25 08:00AM	Mural Oncology Announces Plans to Explore Strategic Alternatives (GlobeNewswire) +133.98%
Mar-28-25 11:13AM	Mural Oncology: Phase 3 Clinical Trial Setback Undermines Company's Future Prospects (Seeking Alpha) -12.59%
Mar-25-25 06:30AM	Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer (GlobeNewswire) -61.62%
Mar-11-25 04:01PM	Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones (GlobeNewswire)
07:00AM	Loading…
Feb-18-25 07:00AM	Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Jan-09-25 04:00PM	Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts (GlobeNewswire)
Dec-03-24 04:15PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-24-24 06:10AM	Raymond James Predicts Up to ~440% Rally for These 2 Strong Buy Stocks (TipRanks)
Nov-20-24 04:15PM	Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer (GlobeNewswire)
Nov-13-24 07:00AM	Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress (GlobeNewswire)
Nov-11-24 07:00AM	Mural Oncology to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Nov-07-24 04:15PM	Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire)
Nov-04-24 04:15PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-07-24 07:00AM	Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire)
04:15PM	Loading…
Oct-02-24 04:15PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-26-24 07:00AM	Mural Oncology's First Virtual Investor Day to Highlight Late-Stage Clinical Progress (GlobeNewswire) -5.31%
Sep-23-24 07:00AM	Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi (GlobeNewswire)
Sep-10-24 07:00AM	Mural Oncology to Host First Virtual Investor Day on September 26, 2024 (GlobeNewswire)
Sep-04-24 04:30PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-27-24 07:00AM	Mural Oncology to Present at Two Upcoming Investor Conferences (GlobeNewswire)
Aug-13-24 07:15AM	Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress (GlobeNewswire)
Aug-02-24 04:15PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.90%
Jul-31-24 07:00AM	Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors (GlobeNewswire) +5.03%
Jul-02-24 04:15PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-05-24 04:15PM	Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference (GlobeNewswire)
Jun-04-24 04:00PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.28%
May-23-24 05:00PM	Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
May-14-24 01:55PM	MURA Stock Earnings: Mural Oncology Reported Results for Q1 2024 (InvestorPlace)
07:00AM	Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
04:00PM	Loading…
May-03-24 04:00PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-24-24 04:00PM	Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-09-24 04:00PM	Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting (GlobeNewswire)
Apr-04-24 04:00PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.87%
Mar-26-24 01:53PM	MURA Stock Earnings: Mural Oncology Reported Results for Q4 2023 (InvestorPlace)
07:00AM	Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-05-24 04:35PM	Mural Oncology Announces Upcoming Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-04-24 04:15PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-24 07:00AM	Mural Oncology to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-05-24 04:30PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-08-24 07:00AM	Mural Oncology Announces Enhancements to Late-Stage Clinical Trials (GlobeNewswire)
Dec-18-23 11:52AM	MURA Stock Earnings: Mural Oncology Reported Results for Q3 2023 (InvestorPlace)

Mural Oncology Plc is a clinical-stage oncology company, which engages in the business of discovering and developing immunotherapies for patients with cancer. Its lead product candidate is the Nemvaleukin Alfa which is an interleukin-2 cytokine designed to capture and expand therapeutic benefits of high-dose recombinant human IL-2. The company was founded on May 31, 2017 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Loew Caroline	Officer	Mar 04 '25	Proposed Sale	3.36	4,313	14,491		Mar 05 05:10 PM
Keson-Brookes Maiken	See Remarks	Mar 05 '25	Sale	3.45	1,469	5,068	73,564	Mar 05 04:49 PM
Keson-Brookes Maiken	See Remarks	Mar 04 '25	Sale	3.36	1,262	4,240	75,033	Mar 05 04:49 PM
Loew Caroline	Chief Executive Officer	Mar 04 '25	Sale	3.36	4,313	14,492	305,590	Mar 05 04:48 PM
Maiken Keson-Brookes	CLO	Mar 05 '25	Proposed Sale	3.43	1,469	5,039		Mar 05 04:03 PM
Goodman Vicki L	Chief Medical Officer	Feb 24 '25	Sale	3.89	13,186	51,294	54,763	Feb 25 04:03 PM
Vicki Goodman	Officer	Feb 24 '25	Proposed Sale	4.04	13,186	53,271		Feb 24 04:11 PM
Keson-Brookes Maiken	See Remarks	Dec 23 '24	Sale	3.27	2,555	8,355	41,295	Dec 26 04:02 PM
Maiken Keson-Brookes	CLO	Dec 23 '24	Proposed Sale	3.25	2,555	8,304		Dec 23 04:19 PM
Loew Caroline	Chief Executive Officer	Dec 17 '24	Sale	3.40	2,763	9,394	237,628	Dec 18 04:06 PM
Goodman Vicki L	Officer	Nov 07 '24	Proposed Sale	3.33	5,069	16,870		Nov 08 04:03 PM
Goodman Vicki L	Chief Medical Officer	Nov 07 '24	Sale	3.33	5,069	16,880	67,949	Nov 08 04:02 PM
Cutler Adam D.	Officer	Oct 31 '24	Proposed Sale	3.41	7,421	25,306		Nov 01 07:08 AM
Cutler Adam D.	Chief Financial Officer	Oct 31 '24	Sale	3.41	7,421	25,306	71,438	Nov 01 07:04 AM
ALTSCHULLER Susan	Director	Aug 14 '24	Buy	3.21	10,000	32,071	10,000	Aug 15 04:15 PM
Keson-Brookes Maiken	See Remarks	Jul 18 '24	Sale	3.41	2,157	7,355	43,850	Jul 18 04:04 PM
Loew Caroline	Chief Executive Officer	Jul 08 '24	Sale	2.91	12,531	36,465	240,391	Jul 08 08:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MURA

Mural Oncology plc

Upgrade your FINVIZ experience